Meeting
2023 ASCO Breakthrough
Differential therapeutic benefit of platinum-doublet chemotherapies with ICIs based on smoking status plus PD-L1 expression in advanced NSCLC patients.
Authors
Akito Fukuda
National Cancer Center Hospital, Chuo-KU, Japan
Akito Fukuda , Tatsuya Yoshida , Ken Masuda , Yuki Shinno , Yusuke Okuma , Yasushi Goto , Hidehito Horinouchi , Noboru Yamamoto , Yuichiro Ohe
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A
Track
Breast Cancer,Central Nervous System Tumors,Developmental Therapeutics,Genitourinary Cancer,Hematologic Malignancies,Thoracic Cancers,Other Malignancies or Topics
Sub Track
Real-World Evidence/Real-World Data
Citation
JCO Global Oncology 9, 2023 (suppl 1; abstr 148)
DOI
10.1200/GO.2023.9.Supplement_1.148
Abstract #
148
Poster Bd #
H10
Abstract Disclosures
Similar Posters
Poster
2021 ASCO Annual Meeting
The role of chemotherapy plus immune checkpoint inhibitors in oncogenic driven non-small cell lung cancer: A University of California Lung Cancer Consortium retrospective study.
First Author: Karen Kelly
Poster
2023 ASCO Annual Meeting
Real-world outcomes of first-line immune checkpoint inhibitors with or without chemotherapy in KRAS G12C altered NSCLC according to PD-L1 status.
First Author: Charu Aggarwal
Poster
2023 ASCO Annual Meeting
Circulating tumor DNA (ctDNA) dynamics and survival outcomes in patients (pts) with advanced non-small cell lung cancer (aNSCLC) and high (>50%) programmed cell death-ligand 1 (PD-L1) expression, randomized to cemiplimab (cemi) vs chemotherapy (chemo).
First Author: Natalie I Vokes
Poster
2023 ASCO Annual Meeting
A novel method that leverages existing data to conduct comparative analyses of competing assets: Sugemalimab and agents targeting the PD-L1/PD-1 axis as an example.
First Author: Antonio Tito Fojo